Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ceftazidime-avibactam

ceftazidime-avibactam

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of ceftazidime-avibactam

8 trials tracked of ceftazidime-avibactam: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 100 citations.

8Trials tracked
2Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 1 Phase 3 1 Phase 2 3 Phase 1 1 Other / NA 2
  1. Phase 3 Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections Completed · 100 cited
  2. Phase 4 Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic Fibrosis Completed · 48 cited
  3. Phase 2 Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs). Completed
  4. Phase 2 A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam Completed
  5. Phase 2 Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs) Completed
  6. Phase 1 A Study of Avycaz (Ceftazidime/Avibactam) Pharmacokinetics/Pharmacodynamics (PK/PD) in Critically Ill Patients Completed
Show 2 more trials
  1. N/A Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receiving CVVHDF Completed
  2. N/A Retrospective Analysis of Real World Use of Ceftazidime-avibactam in the Management of Gram Negative Infections Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Meta-analysis shows carbapenems linked to higher clinical failure in OXA-48-PE infections
Infectious Disease Meta-analysis
Meta-analysis shows carbapenems linked to higher clinical failure in OXA-48-PE infections Doctors found higher death rates when using carbapenems for certain gut bacteria infections
This meta-analysis and review synthesizes data on carbapenem therapy for monomicrobial OXA-48-producing Enterobacterales infections. The aut…
A large review of patients with OXA-48 bacteria showed that carbapenem drugs often failed to work. Newer medicines offered better survival c…
May 24, 2026
Review of Therapeutic Options for Carbapenem-Resistant Enterobacterales
Drug Pipeline RCT
Review of Therapeutic Options for Carbapenem-Resistant Enterobacterales New Weapons Emerge in the Fight Against Deadly Superbugs
This review summarizes available and emerging therapies for carbapenem-resistant Enterobacterales.
New drug combinations offer hope for patients facing deadly superbugs that resist almost all current antibiotics.
Frontiers Apr 18, 2026
Meta-analysis finds no mortality difference between CA and CT for drug-resistant P. aeruginosa infections
Infectious Disease Meta-analysis
Meta-analysis finds no mortality difference between CA and CT for drug-resistant P. aeruginosa infections Which antibiotic works better for dangerous drug-resistant infections?
A meta-analysis of 10 observational studies including 1409 patients with drug-resistant P.
Two powerful new antibiotics show equal survival rates for patients fighting dangerous, drug-resistant infections.
Apr 2, 2026